Aclarion CEO to Showcase NOCISCAN Platform at LSI USA 2026 Conference

Aclarion, Inc. has announced that CEO Brent Ness will attend the LSI USA 2026 conference, scheduled for March 16-20 in Dana Point, California, to present the company's proprietary NOCISCAN platform to investors and industry partners. The appearance underscores the medical device maker's push to gain visibility for its innovative approach to diagnosing painful discs in patients suffering from chronic low back pain—a significant healthcare challenge affecting millions globally.

The NOCISCAN Platform: A Novel Diagnostic Approach

The NOCISCAN platform represents Aclarion's flagship technology offering, combining MR spectroscopy with artificial intelligence and biomarker analysis to help physicians precisely identify symptomatic intervertebral discs in chronic low back pain patients. This capability addresses a critical gap in the diagnostic landscape: while imaging tools like MRI can reveal structural abnormalities in the spine, they cannot reliably distinguish which anatomical findings are actually causing a patient's pain.

The platform's differentiation lies in its use of advanced spectroscopy technology paired with machine learning algorithms designed to detect molecular biomarkers associated with disc pathology. By providing clinicians with objective, AI-driven data, NOCISCAN aims to:

• Enable more accurate patient selection for interventional procedures
• Reduce unnecessary treatments and associated healthcare costs
• Improve clinical outcomes through targeted therapy selection
• Minimize diagnostic uncertainty in a patient population historically prone to misdiagnosis

The chronic low back pain market represents a substantial addressable opportunity, with the condition affecting approximately 10-20% of the adult population globally and driving billions in healthcare expenditures annually.

Market Context: Growing Interest in Diagnostic Innovation

The LSI USA 2026 conference represents a premier venue for life sciences and medtech companies seeking investor engagement and strategic partnership opportunities. The timing of Aclarion's presentation reflects broader industry trends toward diagnostic precision and value-based care models.

The chronic pain diagnostics sector has attracted increasing capital and strategic attention as healthcare systems grapple with the opioid crisis and seek non-pharmaceutical alternatives for managing pain. The broader musculoskeletal and spine diagnostics market is experiencing significant innovation, with competitors and adjacent players developing imaging enhancements, biomarker assays, and predictive algorithms.

Aclarion's positioning within this landscape emphasizes the growing recognition that improved diagnostic accuracy can unlock significant value creation. Reimbursement pathways for advanced diagnostic testing in spine care continue to evolve, with payers increasingly willing to reimburse solutions that demonstrably improve patient selection and reduce overall treatment costs.

The company's willingness to present at a high-profile investor conference suggests confidence in its technology roadmap and commercial trajectory. For investors tracking the medtech sector, NOCISCAN's progress through clinical validation and regulatory approvals represents a key metric to monitor.

Investor Implications: Strategic Visibility and Capital Access

CEO attendance at major industry conferences typically signals several important dynamics:

• Capital readiness: The company may be preparing for financing activities or exploring partnership opportunities
• Technology validation: Public presentation implies confidence in clinical evidence and market differentiation
• Investor education: Direct engagement with the investment community helps build understanding of the market opportunity
• Partnership exploration: Industry conferences facilitate discussions with potential distributors, strategic partners, and acquirers

For shareholders and prospective investors in Aclarion, the LSI USA 2026 presentation offers an opportunity to hear management's perspective on NOCISCAN's clinical performance, reimbursement progress, and commercial timeline. The chronic pain diagnostics sector has demonstrated attractive unit economics and strong demand drivers, making differentiated solutions particularly valuable.

The broader medtech investment landscape currently rewards companies demonstrating clear clinical utility, addressable market size, and realistic paths to profitability. Aclarion's focus on an unmet diagnostic need in a high-prevalence condition aligns with investor preferences for healthcare innovation addressing genuine clinical gaps.

Looking Ahead: Execution Milestones to Watch

Moving forward, investors should track several critical developments for Aclarion, including:

• Clinical validation data supporting NOCISCAN's diagnostic accuracy
• Regulatory clearance progress and pathway clarity
• Reimbursement determinations from major payers
• Commercial partnerships or distribution agreements
• Patient adoption metrics and early clinical evidence of improved outcomes

The company's presence at LSI USA 2026 represents a strategic moment in building market awareness and investor confidence. The success of NOCISCAN's commercialization will ultimately depend on demonstrating robust clinical evidence, navigating regulatory requirements, and establishing favorable reimbursement economics—challenges common across the medtech sector but surmountable for differentiated technologies addressing clear clinical needs.

As the healthcare industry continues accelerating toward precision diagnostics and personalized medicine, Aclarion's positioning in the chronic pain diagnostics space reflects the sector's broader evolution toward data-driven, AI-enhanced clinical decision-making.